title: Nonprostanoid prostacyclin mimetics. 2. 4,5-Diphenyloxazole derivatives.
abstract: 4,5-Diphenyl-2-oxazolenonanoic acid (18b) was synthesized and found to inhibit ADP-induced aggregation of human platelets with an IC50 of 2.5 microM. Acid 18b displaced [3H]iloprost from human platelet membranes in a concentration-dependent fashion, consistent with 18b inhibiting platelet function by acting as a prostacyclin mimetic. By inserting a phenoxy ring into the side-chain moiety of 18b and systematically varying the pattern of substitution and length of the tethers, more potent inhibitors of platelet aggregation were identified. A phenoxy ring inserted centrally in the side chain proved to be the optimal arrangement but significant activity was observed when the aromatic ring was bound directly to the 2 position of the heterocycle. The meta-substituted cis-(ethenylphenoxy)acetic acid 37 is the most potent platelet aggregation inhibitor synthesized as part of this study with an IC50 of 0.18 microM. Acid 37 displaces [3H]iloprost from human platelet membranes with an IC50 of 6 nM. The trans-olefinic isomer of 37 (25p) is 72-fold weaker as an inhibitor of ADP-induced platelet aggregation, but the saturated derivative 25w (BMY 42393) is intermediate in potency. Structure-activity studies using 25w as a template focused on modification of the tethers intervening between the side-chain phenyl ring and the oxazole and carboxylate termini and substitution of the phenyl ring. These studies revealed that biological activity was sensitive to both the identity of the concatenating atoms and the pattern of ring substitution. The structure-activity relationships provide insight into the topographical relationship between the diphenylated oxazole ring and the carboxylic acid terminus that comprise the nonprostanoid prostacyclin mimetic pharmacophore.
authors.affiliation: Department of Cardiovascular Chemistry, Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492.
authors.forename: N A
authors.initials: NA
authors.lastname: Meanwell
authors.forename: M J
authors.initials: MJ
authors.lastname: Rosenfeld
authors.forename: A K
authors.initials: AK
authors.lastname: Trehan
authors.forename: J J
authors.initials: JJ
authors.lastname: Wright
authors.forename: C L
authors.initials: CL
authors.lastname: Brassard
authors.forename: J O
authors.initials: JO
authors.lastname: Buchanan
authors.forename: M E
authors.initials: ME
authors.lastname: Federici
authors.forename: J S
authors.initials: JS
authors.lastname: Fleming
authors.forename: M
authors.initials: M
authors.lastname: Gamberdella
authors.forename: G B
authors.initials: GB
authors.lastname: Zavoico
mesh_terms: D000244:Adenosine Diphosphate / Q000037:antagonists & inhibitors; D002462:Cell Membrane / Q000187:drug effects; D006801:Humans; D010080:Oxazoles / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D013329:Structure-Activity Relationship
chemical_list: D010080:Oxazoles; D010975:Platelet Aggregation Inhibitors; C076919:4,5-diphenyl-2-oxazolenonanoic acid; D000244:Adenosine Diphosphate